

# Active substances set

**Search phrase:** cemiplimab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Tracheal, bronchus, and lung cancer

| | | |
|---|---|---|
| **Cemiplimab** | Cemiplimab as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: - locally advanced NSCLC who are not candidates for definitive chemoradiation, or - metastatic NSCLC. Cemiplimab in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: - locally advanced NSCLC who are not candidates for definitive chemoradiation, or - metastatic NSCLC. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |